Gyon Technologies Capital Management, LP Biogen Inc. Transaction History

Gyon Technologies Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $266,919 - $368,058	-1,371 Reduced 63.41%	791 $211,000
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $405,461 - $482,169	2,162 New	2,162 $441,000
Q1 2022 May 12, 2022	SELL	$193.77 - $244.14 $355,955 - $448,485	-1,837 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$223.92 - $287.77 $1.48 Million - $1.91 Million	-6,621 Reduced 78.28%	1,837 $441,000
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $1.92 Million - $3.07 Million	7,401 Added 700.19%	8,458 $2.93 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $372,928 - $436,907	-1,535 Reduced 59.22%	1,057 $296,000
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $103,954 - $156,477	440 Added 20.45%	2,592 $635,000
Q3 2020 Nov 16, 2020	BUY	$264.77 - $305.71 $569,785 - $657,887	2,152 New	2,152 $610,000
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $652,767 - $828,045	-2,428 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $534,305 - $738,281	2,428 New	2,428 $720,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.